Intriguingly, their most prominent trans-target is interferon lambda (IFNλ) receptor 1 (IFNLR1), whose deficiency lowers the activation of immune cells and reduces organ damage in kidneys without affecting production of antibodies in murine lupus (72). The gene discussed is IFNLR1; the disease is systemic lupus erythematosus.